Table 3a.
Univariate Cox Analysis
| Categoryǂ | LC (univariate) | DFI (univariate) | OS (univariate) | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age at diag. (continuous) | 1.02 (0.95–1.10) | 0.63 | 0.97 (0.94–1.01) | 0.19 | 1.01 (0.96–1.06) | 0.76 |
| Year of Diagnosis | ||||||
| ≤2010 | 2.18 (0.26–13.98) | 0.43 | 1.93 (0.66–5.06) | 0.22 | 1.97 (0.59–5.94) | 0.25 |
| >2010★ | 1 | 1 | 1 | |||
| Tumor size (cm) | ||||||
| Continuous | 1.07 (0.71–1.71) | 0.76 | 1.05 (0.84–1.34) | 0.65 | 1.05 (0.81–1.38) | 0.72 |
| FIGO stage (primary) | ||||||
| III–IV | 1.34 (0.20–26.23) | 0.79 | 0.92 (0.35–2.88) | 0.87 | 0.91 (0.30–3.35) | 0.87 |
| I – II★ | 1 | 1 | 1 | |||
| Grade | ||||||
| 3 | - | 0.25 | 0.89 (0.21–6.09) | 0.89 | - | 0.07 |
| 2 | - | 0.31 | 1.50 (0.38–10.02) | 0.59 | - | 0.07 |
| 1★ | 1 | 1 | 1 | |||
| Histology | ||||||
| SCC | 0.44 (0.06–8.91) | 0.51 | 0.60 (0.19–2.60) | 0.44 | 0.19 (0.06–0.58) | 0.005 |
| Others★ | 1 | 1 | 1 | |||
| Lymphovascular invasion | ||||||
| Yes | - | - | 1.83 (0.63–6.03) | 0.27 | 1.25 (0.39–4.36) | 0.71 |
| Lymph node involvement | ||||||
| Yes | 0.32 (0.04–1.93) | 0.21 | 1.66 (0.62–5.17) | 0.32 | 1.16 (0.38–3.86) | 0.79 |
| BT imaging status | ||||||
| MR-guided ISBT | 0.65 (0.08–4.13) | 0.64 | 0.92 (0.36–2.41) | 0.87 | 0.27 (0.06–0.90) | 0.03 |
| CT-guided ISBT★ | 1 | 1 | 1 | |||
| BT dose (EQD2) | 0.97 (0.81–1.18) | 0.73 | 1.02 (0.93–1.12) | 0.68 | 1.01 (0.91–1.13) | 0.86 |
| Cum. dose (EQD2) | 1.00 (0.79–1.23) | 0.97 | 0.97 (0.87–1.09) | 0.68 | 1.04 (0.91–1.17) | 0.58 |
| Cum. D90 (EQD2) | 1.03 (0.94–1.14) | 0.58 | 1.02 (0.97–1.08) | 0.44 | 1.01 (0.95–1.07) | 0.80 |
★
Referent group;
ǂ
unknown values excluded from the analyses
Key: Diag, Diagnosis; BT, Brachytherapy; ISBT, Interstitial brachytherapy; Adenoca, Adenocarcinoma; Cum, Cumulative: